ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Ikena Oncology's annualized net income for the quarter that ended in Mar. 2024 was $-64.58 Mil. Ikena Oncology's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was $162.55 Mil. Therefore, Ikena Oncology's annualized ROE % for the quarter that ended in Mar. 2024 was -39.73%.
The historical rank and industry rank for Ikena Oncology's ROE % or its related term are showing as below:
IKNA'
s ROE % Range Over the Past 10 Years
Min: -63.87 Med: -43.04 Max: -38.76
Current: -45.39
During the past 5 years, Ikena Oncology's highest ROE % was -38.76%. The lowest was -63.87%. And the median was -43.04%.
IKNA's ROE % is ranked worse than 51.32% of 1360
companies
in the Biotechnology industry
Industry Median: -43.445
vs IKNA: -45.39
Ikena Oncology ROE % Historical Data
The historical data trend for Ikena Oncology's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ikena Oncology's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ikena Oncology's ROE % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ikena Oncology's ROE % distribution charts can be found below:
* The bar in red indicates where Ikena Oncology's ROE % falls into.
Ikena Oncology ROE % Calculation
Ikena Oncology's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2024) net income data.
ROE % is displayed in the 30-year financial page.
Ikena Oncology (NAS:IKNA) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Ikena Oncology ROE % Related Terms
Thank you for viewing the detailed overview of Ikena Oncology's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Ikena Oncology (Ikena Oncology) Business Description
Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients. its other product candidates are IK-175 and IK-595.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IKNA has been successfully added to your 